Evaluation of molecular markers in low-grade diffuse astrocytomas: Loss of p16 and retinoblastoma protein expression is associated with short survival

American Journal of Surgical Pathology

Volumn 26, Issue 4, 2002, Pages 472-478

  Hilton, David A ^a   Penney, Mark ^a   Evans, Barry ^a   Sanders, Hilary ^a   Love, Seth ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Astrocytoma; p16; p53; Ploidy; Prognosis; Retinoblastoma

Indexed keywords

DIGOXIGENIN; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN ANTIBODY; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME LOSS; EVALUATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LABELING INDEX; MAJOR CLINICAL STUDY; MONOSOMY; POLYPLOIDY; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

ASTROCYTOMA; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; RECEPTORS, CELL SURFACE; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036205159     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200204000-00009     Document Type: Article

References (36)

1. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytomas
2. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors
3. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value
4. Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas
5. Prognostic indicators in a range of astrocytic tumours: An immunohistochemical study with Ki-67 and p53 antibodies
6. Identification of a chromosome 18q gene that is altered in colorectal carcinoma
7. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
8. Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation
9. Restoration of wild type p16 down regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
10. The retinoblastoma gene is involved in malignant progression of astrocytomas
11. Accumulation of p53 and Ki-67 expression do not predict the survival of patients with fibrillary astrocytomas, or the response of these tumors to radiotherapy
12. p53 protein in low-grade astrocytomas: A study with long-term follow-up
13. Prognostic implications of p53 protein, epidermal growth factor receptor and Ki-67 labeling in brain tumours
14. Prognostic value of the expression of tumor suppressor genes p53, p21, p 16 and pRb, and Ki-67 labeling in high grade astrocytomas treated with radiotherapy
15. p53: The cellular gatekeeper for growth and division
16. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma
17. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma
18. The significance of the expression of tumor suppressor gene DCC in human gliomas
19. Malignant astrocytomas with homozygous CDKN2/p16 deletions have higher Ki-67 proliferation indices
20. Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival, formalin-fixed, paraffin-embedded tissue and nonfluorescent light microscopy
21. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas
22. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival
23. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression
24. Chromosomal composition of a series of 22 human low-grade gliomas
25. Loss of DCC expression and glioma progression
26. Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas
27. Expression of the tumour suppressor gene DCC in human gliomas
28. Proliferative activity and prognosis of low-grade astrocytomas
29. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
30. Clonal expansion of p53 mutant cells is associated with brain tumor progression
31. Alterations of retinoblastoma, p53, p16 (CDKN2) and p15 genes in human astrocytomas
32. p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression
33. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography
34. Subsets of glioblastoma multiforme defined by molecular genetic analysis
35. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies